A phase III, multicentre, randomised, double-blinded, placebo-controlled clinical trial of SpironolacTOne and famciclovir in Progressive Multiple Sclerosis: the STOP-MS trial

  • Broadley, Simon (Recipient), Sun, Jing (Recipient), Taylor, Bruce (Recipient), Barnett, Michael (Recipient), Chataway, Jeremy (Recipient), Parmar, Mahesh (Recipient), Steinman, Lawrence (Recipient), Tscharke, David Carl (Recipient), Kalincik, Tomas (Recipient), Jokubaitis, ilija (Recipient), Smith, Corey (Recipient), Campbell, Julie (Recipient), Li, Vivien (Recipient), Parnell, Grant (Recipient) & Ramanathan, Sudarshini (Recipient)

Prize: GrantSuccessful

Description

MRFF - Multiple Sclerosis Research Grant - (MRF2025006)
Total project value: $2,333,362
Degree of recognitionNational
Granting OrganisationsAustralian Government

    Fingerprint